Cargando…
Targeting NOX4 disrupts the resistance of papillary thyroid carcinoma to chemotherapeutic drugs and lenvatinib
Advanced differentiated thyroid cancer cells are subjected to extreme nutritional starvation which contributes to develop resistance to treatments; however, the underlying mechanism remains unclear. Cells were subjected to serum deprivation by culture in medium containing 0.5% fetal bovine serum. A...
Autores principales: | Tang, Ping, Sheng, Jianfeng, Peng, Xiujuan, Zhang, Renfei, Xu, Tao, Hu, Jun, Kang, Yuexi, Wu, Baiyi, Dang, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990679/ https://www.ncbi.nlm.nih.gov/pubmed/35396551 http://dx.doi.org/10.1038/s41420-022-00994-7 |
Ejemplares similares
-
Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma
por: Yamazaki, Haruhiko, et al.
Publicado: (2019) -
Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
por: Takinami, Masaki, et al.
Publicado: (2020) -
A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy
por: Iwasaki, Hiroyuki, et al.
Publicado: (2020) -
NADPH oxidase NOX4 is a glycolytic regulator through mROS-HIF1α axis in thyroid carcinomas
por: Tang, Ping, et al.
Publicado: (2018) -
Successful Treatment by Surgery and Lenvatinib of a Patient with Adrenal Metastasis of Papillary Thyroid Cancer
por: Nakamura, Hajime, et al.
Publicado: (2020)